Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

82 study records (showing up to 30 per record type)

• Registered trial NCT00164749 Phase 1 / Phase 2 Completed (results not assessed here)
  A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease
  Condition or outcome area: Alzheimer's Disease
  2004-10 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05594355 Phase 4 Not completed: Active Not Recruiting
  Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI
  Condition or outcome area: Mild Cognitive Impairment (MCI)
  2021-04-16 · Subject: Bai Guo Shu Pi; 白果树皮; Ginkgo Bark; Ginkgo Biloba · open the herb record · ClinicalTrials.gov
• Registered trial NCT05398874 Completed (results not assessed here)
  Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Knee Osteoarthritis
  Condition or outcome area: Knee Osteoarthritis
  2021-11-01 · Subject: Bai Guo Shu Pi; 白果树皮; Ginkgo Bark; Ginkgo Biloba · open the herb record · ClinicalTrials.gov
• Registered trial NCT04685005 Completed (results not assessed here)
  "WakeUp" for Vigilance Following Lunch
  Condition or outcome area: Fatigue
  2018-11-01 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00276510 Phase 4 Completed (results not assessed here)
  A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints
  Condition or outcome area: Memory Disorders, Age-Related|Retention Disorders, Cognitive
  2002-02 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00814346 Phase 2 Completed (results not assessed here)
  Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
  Condition or outcome area: Alzheimer's Disease|Cognitive Impairment
  2008-10 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT02807649 Completed (results not assessed here)
  Effect of Ginko and Cistanche Against Fatigue Symptoms
  Condition or outcome area: Mental Fatigue|Fatigue|Chronic Fatigue Syndrome
  2015-05 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00276341 Phase 3 Completed (results not assessed here)
  Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis
  Condition or outcome area: Multiple Sclerosis, Relapsing-Remitting
  2003-08-26 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00029692 Phase 2 Completed (results not assessed here)
  Effects of Ginseng and Ginkgo on Drug Disposition in Man
  Condition or outcome area: Healthy
  2002-03 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00029692 Phase 2 Completed (results not assessed here)
  Effects of Ginseng and Ginkgo on Drug Disposition in Man
  Condition or outcome area: Healthy
  2002-03 · Subject: Ren Shen; 人参; Ginseng ;Ginseng; Radix et Rhizoma Ginseng;Ginseng Radix et Rhizoma · open the herb record · ClinicalTrials.gov
• Registered trial NCT01160692 Phase 3 Completed (results not assessed here)
  A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment
  Condition or outcome area: Age-Related Memory Disorders
  2006-02 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT01536210 Phase 3 Completed (results not assessed here)
  Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)
  Condition or outcome area: Mental Disorders
  2011-12 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT01201187 Phase 3 Completed (results not assessed here)
  Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD
  Condition or outcome area: Mental Disorders
  2010-03 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT01201187 Phase 3 Completed (results not assessed here)
  Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD
  Condition or outcome area: Mental Disorders
  2010-03 · Subject: Ren Shen; 人参; Ginseng ;Ginseng; Radix et Rhizoma Ginseng;Ginseng Radix et Rhizoma · open the herb record · ClinicalTrials.gov
• Registered trial NCT00164749 Phase 1 / Phase 2 Completed (results not assessed here)
  A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease
  Condition or outcome area: Alzheimer's Disease
  2004-10 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00070161 Phase 2 Completed (results not assessed here)
  Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
  Condition or outcome area: Brain and Central Nervous System Tumors|Radiation Toxicity
  2001-07-01 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00824512 Phase 2 Completed (results not assessed here)
  Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
  Condition or outcome area: Friedreich Ataxia
  2008-06 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT05002036 Phase 4 Completed (results not assessed here)
  Management of Dry Eye Disease After Cataract Surgery With Topical Hyaluronic Acid and Gingko Biloba
  Condition or outcome area: Dry Eye Syndromes
  2021-02-01 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT02321475 Completed (results not assessed here)
  EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
  Condition or outcome area: Cognitive Disorders
  2014-06 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00276380 Phase 3 Completed (results not assessed here)
  A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke
  Condition or outcome area: Stroke, Acute|Neurological Impairment
  2003-02 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT04525144 Phase 2 Not completed: Recruiting
  EGb 761 in the Syndrome of MCI With Concomitant CVD
  Condition or outcome area: Mild Cognitive Impairment|Cerebrovascular Disease
  2020-10-26 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00046891 Phase 3 Completed (results not assessed here)
  EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
  Condition or outcome area: Breast Cancer|Neurotoxicity
  2002-12 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT02882438 Phase 1 Not completed: Unknown
  Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis
  Condition or outcome area: Foot Infection Tinea Pedis
  2016-01 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00103012 Phase 4 Completed (results not assessed here)
  Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers
  Condition or outcome area: Healthy
  2005-01 · Subject: Song Guo Ju; 松果菊; Echinacea; Echinacea Purpurea · open the herb record · ClinicalTrials.gov
• Registered trial NCT00103012 Phase 4 Completed (results not assessed here)
  Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers
  Condition or outcome area: Healthy
  2005-01 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00103012 Phase 4 Completed (results not assessed here)
  Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers
  Condition or outcome area: Healthy
  2005-01 · Subject: Ren Shen; 人参; Ginseng ;Ginseng; Radix et Rhizoma Ginseng;Ginseng Radix et Rhizoma · open the herb record · ClinicalTrials.gov
• Registered trial NCT00841321 Phase 2 Completed (results not assessed here)
  Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis
  Condition or outcome area: Multiple Sclerosis|Cognitive Ability, General
  2009-01 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT02604381 Phase 2 Completed (results not assessed here)
  A Study on the Efficacy of Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Leaf Extract in Adults With Osteoarthritis of the Knee.
  Condition or outcome area: Osteoarthritis of the Knee
  2015-11 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT00446485 Phase 4 Completed (results not assessed here)
  Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency
  Condition or outcome area: Mild Cognitive Impairment|Cerebrovascular Insufficiency
  2007-05 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Registered trial NCT01139281 Phase 2 Completed (results not assessed here)
  The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
  Condition or outcome area: Ototoxicity|Hearing Loss
  2007-06 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf;Ginkgo Folium; Folium Ginkgo;Ginkgo Folium · open the herb record · ClinicalTrials.gov
• Systematic review registration CRD42023445014 Registered protocol, no results here: Review Ongoing
  Meta-analysis of the efficacy and safety of Ginkgo diterpene lactoneoside combined with butylphthalide in the treatment of acute cerebral infarction
  Condition or outcome area: Ginkgolide Meglumine Injection (GMI), as a traditional Chinese medicine compound preparation, has been widely used in the treatment of cerebrovascular diseases in China and has shown certain therapeutic effects. Danaparoid sodium, a commonly used neuroprotective drug, is believed to have therapeutic effects against cerebral ischemia. Although some trials and studies have reported that the combination of Ginkgolide Meglumine and Danaparoid sodium has higher clinical efficacy in the treatment of a
  2023-07-24 · Subject: Butylphthalide; 6066-49-5; 3-n-Butylphthalide; 3-BUTYLPHTHALIDE; 3-butylisobenzofuran-1(3H)-one; Phthalide, 3-butyl-; 1(3H)-Isobenzofuranone, 3-butyl-; 3-N-BUTYLPHATHLIDE; 3-Butyl-1(3H)-isobenzofuranone; FEMA No. 3334 · open the ingredient record
• Systematic review registration CRD42023449589 Registered protocol, no results here: Review Ongoing
  Systematic evaluation of ginkgo biloba extract in the treatment of vascular dementia
  Condition or outcome area: Vascular dementia (VD) refers to a syndrome of central nervous system damage related to blood vessels, often caused by various cerebrovascular diseases. Its clinical manifestations include decreased intelligence and social life abilities, accompanied by changes in personality and emotions [1], which greatly endangers the mental health and quality of life of the elderly and increases the personal care burden on families and society.
  2023-08-10 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023423789 Registered protocol, no results here: Review Ongoing
  Ginkgo biloba leaf extract EGb 761® for the treatment of various diseases: An overview of systematic reviews
  Condition or outcome area: This overview will consider systematic reviews with or without meta-analyses describing oral EGb 761® intake for clinical reasons, as prevention, or for health promotion.
  2023-05-15 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023486259 Registered protocol, no results here: Review Ongoing
  Systematic review and network meta-analysis of Ginkgo biloba extract preparations for ischemic stroke
  Condition or outcome area: Globally, one third, or 17.9 million, of total annual deaths are attributable to cardiovascular disease (CVD). The incidence of cardiovascular disease has declined since the middle of the last century, but less so in women than in men. CVD, such as stroke, transient ischemic attack, and coronary heart disease, share common (traditional) risk factors, including hypertension, hyperglycemia, hyperlipidemia, hyperuricemia, and obesity. Western medicines, such as hypotensive, hypoglycemic, lipid-lowe
  2023-12-05 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023486234 Registered protocol, no results here: Review Ongoing
  Efficacy and Safety of Ginkgo biloba Extract Injections in Patients with Acute Ischemic Stroke Undergoing Intravenous Thrombolysis: A Systematic Review and Meta-Analysis
  Condition or outcome area: Acute Ischemic Stroke
  2023-12-05 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023485940 Registered protocol, no results here: Review Ongoing
  Efficacy and safety evaluation of Ginkgo biloba extract in the treatment of cerebral hemorrhage：A systematic review, meta-analysis
  Condition or outcome area: cerebral hemorrhage
  2023-12-03 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023474678 Registered protocol, no results here: Review Ongoing
  The effect of Ginkgo biloba extract combined with donepezil on patients with vascular dementia:A protocol for systematic review and meta-analysis
  Condition or outcome area: Vascular dementia is a vascular cognitive impairment, making it the second most common type of dementia after Alzheimer's disease. There are currently no uniform standards for dementia treatment. Common treatments include cholinesterase inhibitors (such as Donepezil, galantamine, and NMDA receptor antagonists such as Memantine), which have been shown to improve cognitive function and score higher on behavioral scales in patients to varying degrees. However, these drugs can produce a variety of a
  2023-10-31 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023455792 Registered protocol, no results here: Review Ongoing
  The efficacy and safety of Ginkgo biloba extract combined with ACEI/ARB on diabetic nephropathy: a systematic review and meta-analysis
  Condition or outcome area: Diabetic nephropathy is one of the most severe complications of diabetes and is a primary cause of chronic kidney disease and end-stage renal disease. It is characterized by hyperfiltration and albuminuria in the early phase which is followed by progressive renal function decline, renal tubular epithelial cell hypertrophy, and tubulointerstitial fibrosis. The consequences of diabetic nephropathy extend beyond the kidneys, escalating the chances of cardiovascular diseases, nerve damage, and visio
  2023-08-30 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023447270 Registered protocol, no results here: Review Ongoing
  An update systematic review and meta-analysis on the efficacy of tricyclic antidepressants (TCAs), modafinil, bupropion, buspirone, and ginkgo biloba extract in treating attention deficit hyperactivity disorder (ADHD)
  Condition or outcome area: Attention deficit hyperactivity disorder (ADHD).
  2023-07-31 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023446824 Registered protocol, no results here: Review Ongoing
  A systematic review and meta-analysis of the effects of plant-based substances and nutritional supplements therapy on tinnitus severity perception in adult patients
  Condition or outcome area: Tinnitus in adults with chronic or acute tinnitus through these domains: a) Tinnitus severity measured through subjective assessment of tinnitus severity, frequency or annoyance using visual analogue scales (VAS). b) Tinnitus loudness can be measured through performance-based procedures such as tinnitus loudness or pitch matching. c) The impact of tinnitus on patients’ daily life can be measured on standardized self-reported questionnaires.
  2023-07-31 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023435565 Registered protocol, no results here: Review Ongoing
  Systematic evaluation of ginkgo biloba extract in the treatment of vascular dementia
  Condition or outcome area: Vascular dementia (VD) refers to a syndrome of central nervous system damage related to blood vessels, often caused by various cerebrovascular diseases. Its clinical manifestations include decreased intelligence and social life abilities, accompanied by changes in personality and emotions [1], which greatly endangers the mental health and quality of life of the elderly and increases the personal care burden on families and society.
  2023-08-07 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023423363 Registered protocol, no results here: Review Completed not published
  Systematic review, meta-analysis and sequential analysis of ginkgo biloba extract in the treatment of IPF
  Condition or outcome area: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic interstitial lung disease characterized by extensive pulmonary remodeling caused by abnormal deposition of extracellular matrix [1]. The main clinical manifestations of IPF are dry cough, dyspnea, progressive deterioration, and decreased lung function. The etiology of IPF is still unclear, and it mainly occurs in middle-aged and elderly people. The incidence of IPF is (6.8-16.3) per 100 000, and there are about 40 000 new cases diagnosed
  2023-05-16 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023418053 Registered protocol, no results here: Review Ongoing
  Systematic review and meta-analysis of the efficacy of non-clozapine treatment options for symptoms of psychosis in treatment resistant schizophrenia
  Condition or outcome area: Treatment-resistant schizophrenia defined as the persistence of symptoms despite two or more trials of antipsychotic medication of adequate dose and duration with documented adherence.
  2023-05-15 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023414700 Registered protocol, no results here: Review Ongoing
  Supplements improve cognitive ability in patients with mild cognitive impairment or Alzheimer' s disease: a systematic review and network meta-analysis of randomized controlled trials.
  Condition or outcome area: Mild cognitive impairment (MCI) refers to a state of cognitive deterioration that precedes the clinical diagnosis of Alzheimer' s disease (AD) and other dementias, which does not yet compromise daily functioning. Now, the prevalence and incidence of dementia are increasing with the aging of the population. There have been studies on the improvement of cognitive function in patients with MCI or AD. For example, studies have found that vitamins and minerals have many functions in the nervous syste
  2023-04-17 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42023413630 Registered protocol, no results here: Review Ongoing
  The efficacy and safety of pharmacological interventions in treating vascular cognitive impairment:protocol for a systematic review and network meta-analysis
  Condition or outcome area: Vascular cognitive impairment(VCI) was proposed to describe a broad range of cognitive dysfunction resulting from all types of vascular pathology, from mild cognitive impairment to dementia. Currently, randomized controlled trials (RCTs) investigating pharmacological interventions for vascular cognitive impairment have been designed and implemented continuously, but no standard treatments have been approved for VCI. And these RCTs have suggested diverse results of pharmacological interventions a
  2023-05-07 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42022361487 Registered protocol, no results here: Review Ongoing
  Ginkgo leaf preparations (oral and injectable) in the treatment of unstable angina pectoris: A systematic review and network Meta-analysis
  Condition or outcome area: Unstable angina pectoris.
  2022-10-04 · Subject: SHU XUE NING Zhu She Ye; 舒血宁注射液; Shu Xue Ning Injection · open the formula record
• Systematic review registration CRD42020197727 Registered protocol, no results here: Review Ongoing
  Curative effect and safety of sodium nitroprusside or combined Ginkgodamole and nitroglycerin on hypertensive cerebropathia : a meta-analysis
  Condition or outcome area: When blood pressure is higher than the regulatory threshold(central arterial pressure > 140 mmHg)， fibrous protein-like necrosis will occur to the central histocytes, leading to vessel injury, and eventually cerebral ischemia and encephaledema. This may cause an increase in intracranial pressure and hypertensive cerebrophia. The hypertensive cerebrophia is often expressed as a kind of nerve malfunction, such as nausea, vomiting, headache, confusion of consciousness, and in the most severest c
  2020-08-08 · Subject: Sodium; 7440-23-5; Na; Natrium; Sodio; sodium atom; 116001-96-8; 11Na; DTXSID1049774; CHEBI:26708 · open the ingredient record
• Systematic review registration CRD42015023354 Registered protocol, no results here: Review Ongoing
  Comparative efficacy and safety of Huperzine A and Ginkgo biloba extract in patients with Alzheimer’s disease: a network meta-analysis of randomized controlled trials
  Condition or outcome area: Alzheimer disease
  2015-06-10 · Subject: (-)-huperzine a; (-)-Selagine; Huperzine A; 102518-79-6; Fordine; HuperzineA; 120786-18-7; C15H18N2O; (1R,9R)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one; (1R,9R,13Z)-1-Amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one · open the ingredient record
• Systematic review registration CRD42015023354 Registered protocol, no results here: Review Ongoing
  Comparative efficacy and safety of Huperzine A and Ginkgo biloba extract in patients with Alzheimer’s disease: a network meta-analysis of randomized controlled trials
  Condition or outcome area: Alzheimer disease
  2015-06-10 · Subject: Huperzine a; Huperzine A; (-)-huperzine A; 102518-79-6; (-)-huperazine A; Selagine; Huperzin A; L-huperzine A; (-)-Selagine; Hup A · open the ingredient record
• Systematic review registration CRD42015023354 Registered protocol, no results here: Review Ongoing
  Comparative efficacy and safety of Huperzine A and Ginkgo biloba extract in patients with Alzheimer’s disease: a network meta-analysis of randomized controlled trials
  Condition or outcome area: Alzheimer disease
  2015-06-10 · Subject: Huperzine; (+/-)-Huperzine A; 120786-18-7; Huperzine A; (+/-)-Huperazine A; Fordine; ( inverted exclamation markA)-Huperzine A; HuperzineA; Huperizine A; Huperzine-A · open the ingredient record
• Systematic review registration CRD42021260215 Registered protocol, no results here: Review Ongoing
  Effect of diterpene ginkgolides meglumine injection on NIHSS in patients with acute cerebral infarction: a systematic review and meta-analysis
  Condition or outcome area: acute ischemic infarction
  2021-07-10 · Subject: Ginkgolides · open the ingredient record
• Systematic review registration CRD42020141825 Registered protocol, no results here: Review Ongoing
  Combined therapy of hypertensive nephropathy with ginkgo leaf extract and dipyridamole injection and antihypertensive drugs: a systematic review and meta-analysis
  Condition or outcome area: Hypertension is a risk factor for stroke, coronary artery disease, heart failure, peripheral vascular disease, and chronic kidney disease (CKD). Elevated blood pressure (BP) was the leading global contributor to premature death in 2015, accounting for almost 10 million deaths and over 200 million disability-adjusted life years. Hypertensive kidney disease is the second leading cause of end-stage renal disease (ESRD) after diabetes mellitus. Chronic kidney failure is a global disease: at the end
  2020-03-09 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42018107112 Registered protocol, no results here: Review Ongoing
  Ginkgo leaf extract and dipyridamole injection as adjuvant treatment for acute cerebral infarction
  Condition or outcome area: Acute cerebral infarction.
  2018-08-31 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42022378970 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of ginkgo biloba preparations in the treatment of Alzheimer's disease: a meta-analysis of clinical trials
  Condition or outcome area: Alzheimer’s disease is a progressive and insidious neurodegenerative disease (Zhou, 2010) that is most common among the elderly. With economic development and advances in medical care, human life expectancy has significantly increased, leading to an increase in the prevalence of Alzheimer’s disease
  2022-12-13 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42022375806 Registered protocol, no results here: Review Ongoing
  A systematic review and meta-analysis of ginkgo biloba extract as a treatment for idiopathic pulmonary fibrosis
  Condition or outcome area: There is no explanation for the cause of idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive, fibrotic, interstitial lung disease.It is a sequela of severe cases of the novel coronavirus disease (COVID-19) in the 2019 global outbreak and has been recognized as a risk factor for severe COVID-19 disease. Its clinical manifestations are progressively worsening dyspnea, restrictive ventilatory dysfunction and gas exchange disorders, hypoxemia and eventually respiratory failure and d
  2022-11-25 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42022374851 Registered protocol, no results here: Review Ongoing
  The effect of ginkgo biloba on glycemic control in adults
  Condition or outcome area: In this review the effect of gingko biloba on glycemic control will be studied.
  2022-12-26 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42022363313 Registered protocol, no results here: Review Ongoing
  Chinese Herbal Medicine Ginkgo biloba Leaf Preparation for Ischemic Stroke: An Overview of Systematic Reviews and Meta-Analyses
  Condition or outcome area: Stroke is a leading cause of disability and death and has become a global public health burden. Ischemic stroke is the main subtype of stroke, with a proportion of more than 80%. Traditional Chinese medicine therapy has been widely used as a potential complementary therapy in China. For example, Ginkgo biloba leaf preparation (GBLP) is considered to be a possible effective drug for ischemic stroke.
  2022-10-08 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42022361487 Registered protocol, no results here: Review Ongoing
  Ginkgo leaf preparations (oral and injectable) in the treatment of unstable angina pectoris: A systematic review and network Meta-analysis
  Condition or outcome area: Unstable angina pectoris.
  2022-10-04 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42022346140 Registered protocol, no results here: Review Ongoing
  The role of the administration of ginkgo biloba extract in the functional status of patients recovering from an acute stroke
  Condition or outcome area: Cardiovascular; Neurology
  2022-09-20 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Systematic review registration CRD42022332298 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of standardized ginkgo biloba extract as adjunctive therapy for cerebral hemorrhage: a systematic review and meta-analysis
  Condition or outcome area: Intracerebral hemorrhage (ICH) is a common acute cerebrovascular disease caused by Intracerebral hemorrhage (ICP) due to non-traumatic factors. With the development of population aging, its incidence is increasing year by year. ICH has the characteristics of rapid onset, rapid progression, high disability and mortality. Although active treatment is carried out, most of the surviving patients are left with varying degrees of neurological dysfunction, which seriously affects the quality of life of
  2022-05-23 · Subject: Yin Xing Ye; 银杏叶; Ginkgo Leaf; Ginkgo Folium; Folium Ginkgo · open the herb record
• Publication PMID 34456714 Research model: Animal Experiment
  Isovitexin Inhibits Ginkgolic Acids-Induced Inflammation Through Downregulating SHP2 Activation
  Condition or outcome area: Ear swelling; inflammatory diseases; GA-induced inflammatory problems; splenomegaly; contact dermatitis; GA-induced contact dermatitis; inflammatory cell infiltration
  Front Pharmacol · 2021 · Subject: Isovitexin; 38953-85-4; Saponaretin; 29702-25-8; Homovitexin; 6-Glucosylapigenin; Apigenin-6-C-glucoside; 6-C-Glucosylapigenin; Isoavroside; Avroside · open the ingredient record · DOI 10.3389/fphar.2021.630320
• Publication PMID 36162256 Research model: Animal & Cell Experiment
  Isoginkgetin, a bioactive constituent from Ginkgo Biloba, protects against obesity-induced cardiomyopathy via enhancing Nrf2/ARE signaling
  Condition or outcome area: obesity; cardiomyopathy; cardiac dysfunction; Obesity-induced metabolic cardiomyopathy; heart failure; cardiac diastolic dysfunction; mitochondrial defects; obese; lipotoxicity
  Redox Biol · 2022 · Subject: Isoginkgetin; 548-19-6; iso-ginkgetin; 4',4'''-Dimethylamentoflavone; 8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-methoxyphenyl]-5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; CHEBI:79087; DTXSID00203271; 3''',8-Biflavone, 5,5'',7,7''-tetrahydroxy-4',4'''-dimethoxy-; 8-(5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-methoxyphenyl)-5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; 8-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-methoxyphenyl]-5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one · open the ingredient record · DOI 10.1016/j.redox.2022.102485
• Publication PMID 33167504 Research model: Cell Experiment
  Anti-neoplastic Effect of Ginkgolide C through Modulating c-Met Phosphorylation in Hepatocellular Carcinoma Cells
  Condition or outcome area: liver cancer; tumor; hepatocellular carcinoma
  Int J Mol Sci · 2020 · Subject: Ginkgolide c; Ginkgolide C (>90%); 15291-76-6; 1,7-Dihydroxy-ginkgolide A; (1R,3R,6R,7S,8S,9R,10S,11R,12S,13S,16S,17R)-8-Tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione; SCHEMBL16452771; AMOGMTLMADGEOQ-PYLUGNSCSA-N; MFCD02094178; MFCD06642603; AKOS025311463 · open the ingredient record · DOI 10.3390/ijms21218303
• Publication PMID 35837278 Research model: Animal & Cell Experiment
  Ginkgolide B Protects Against Ischemic Stroke via Targeting AMPK/PINK1
  Condition or outcome area: neurodegenerative diseases; ischemic stroke; Alzheimer's disease
  Front Pharmacol · 2022 · Subject: Ginkgolide b; Gingko lactone; 15291-77-7; Ginkolide B; BN 52021; GinkgolideB; SR-01000597598; bn52021; Ginklide B; C20H24O10 · open the ingredient record · DOI 10.3389/fphar.2022.941094
• Publication PMID 34944919 Research model: Cell Experiment
  Ginkgolide B Regulates CDDP Chemoresistance in Oral Cancer via the Platelet-Activating Factor Receptor Pathway
  Condition or outcome area: cancer; oral squamous cell carcinoma
  Cancers (Basel) · 2021 · Subject: Ginkgolide b; Gingko lactone; 15291-77-7; Ginkolide B; BN 52021; GinkgolideB; SR-01000597598; bn52021; Ginklide B; C20H24O10 · open the ingredient record · DOI 10.3390/cancers13246299
• Publication PMID 33679323 Research model: Animal Experiment
  Ginkgolide B Maintains Calcium Homeostasis in Hypoxic Hippocampal Neurons by Inhibiting Calcium Influx and Intracellular Calcium Release
  Front Cell Neurosci · 2021 · Subject: Ginkgolide b; Gingko lactone; 15291-77-7; Ginkolide B; BN 52021; GinkgolideB; SR-01000597598; bn52021; Ginklide B; C20H24O10 · open the ingredient record · DOI 10.3389/fncel.2020.627846
• Publication PMID 33452698 Research model: Animal & Cell Experiment
  Neuroprotective effects of Ginkgolide B in focal cerebral ischemia through selective activation of prostaglandin E2 receptor EP4 and the downstream transactivation of epidermal growth factor receptor
  Condition or outcome area: middle cerebral artery occlusion
  Phytother Res · 2021 · Subject: Ginkgolide b; Gingko lactone; 15291-77-7; Ginkolide B; BN 52021; GinkgolideB; SR-01000597598; bn52021; Ginklide B; C20H24O10 · open the ingredient record · DOI 10.1002/ptr.7018
• Publication PMID 36396110 Research model: Cell Experiment
  CCL2-targeted ginkgolic acid exerts anti-glioblastoma effects by inhibiting the JAK3-STAT1/PI3K-AKT signaling pathway
  Condition or outcome area: tumor; tumors; intracranial tumor; Glioblastoma
  Life Sci · 2022 · Subject: Ginkgoic acid; Ginkgolic acid; 22910-60-7; Ginkgolic acid C15:1; Ginkgolic acid I; Gingkolic Acid; 2-hydroxy-6-[(Z)-pentadec-8-enyl]benzoic acid; 6-[(8Z)-Pentadecenyl]-salicylic acid; Romanicardic acid; CHEBI:5354 · open the ingredient record · DOI 10.1016/j.lfs.2022.121174
• Publication PMID 35707278 Research model: Animal Experiment
  Ginkgolic acid improves bleomycin-induced pulmonary fibrosis by inhibiting SMAD4 SUMOylation
  Condition or outcome area: fibrosis; myocardial infarction; chronic respiratory disease; Idiopathic pulmonary fibrosis; cardiac fibrosis
  Oxid Med Cell Longev · 2022 · Subject: Ginkgoic acid; Ginkgolic acid; 22910-60-7; Ginkgolic acid C15:1; Ginkgolic acid I; Gingkolic Acid; 2-hydroxy-6-[(Z)-pentadec-8-enyl]benzoic acid; 6-[(8Z)-Pentadecenyl]-salicylic acid; Romanicardic acid; CHEBI:5354 · open the ingredient record · DOI 10.1155/2022/8002566
• Publication PMID 33508304 Research model: Cell Experiment
  Ginkgoic acid impedes gastric cancer cell proliferation, migration and EMT through inhibiting the SUMOylation of IGF-1R
  Condition or outcome area: cancers; gastric cancer; cancer
  Chem Biol Interact · 2021 · Subject: Ginkgoic acid; Ginkgolic acid; 22910-60-7; Ginkgolic acid C15:1; Ginkgolic acid I; Gingkolic Acid; 2-hydroxy-6-[(Z)-pentadec-8-enyl]benzoic acid; 6-[(8Z)-Pentadecenyl]-salicylic acid; Romanicardic acid; CHEBI:5354 · open the ingredient record · DOI 10.1016/j.cbi.2021.109394
• Publication PMID 33113504 Research model: Cell Experiment
  Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer
  Condition or outcome area: ferroptosis; Ferroptosis; cancer; advanced and non-targetable non-small-cell lung cancer
  Phytomedicine · 2021 · Subject: Ginkgetin; 481-46-9; 7,4'-Dimethylamentoflavone; Amentoflavone 7,4'-dimethyl ether; CHEBI:5353; HY5EZW8269; 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxochromen-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)chromen-4-one; DTXSID70197416; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-(5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl)-2-(4-hydroxyphenyl)-; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)- · open the ingredient record · DOI 10.1016/j.phymed.2020.153370
• Publication PMID 32410995 Research model: Animal & Cell Experiment
  Kaempferol, a Major Flavonoid in Ginkgo Folium, Potentiates Angiogenic Functions in Cultured Endothelial Cells by Binding to Vascular Endothelial Growth Factor
  Front Pharmacol · 2020 · Subject: Campherol; Kaempferol; kaempferol; 520-18-3; Kaempherol; Robigenin; Populnetin; Rhamnolutein; Trifolitin; Kempferol · open the ingredient record · DOI 10.3389/fphar.2020.00526
• Publication PMID 36091773 Research model: Others
  MiR-146b-5p/TRAF6 axis is essential for Ginkgo biloba L. extract GBE to attenuate LPS-induced neuroinflammation
  Condition or outcome area: Neuroinflammation; cerebral and peripheral blood circulation disorders; neurodegenerative diseases; tumor; Alzheimer's disease
  Front Pharmacol · 2022 · Subject: Bai Guo Shu Pi; 白果树皮; Ginkgo Bark; Ginkgo Biloba · open the herb record · DOI 10.3389/fphar.2022.978587
• Publication PMID 35631163 Research model: Clinical & Cell Experiment
  Ginkgo Biloba Leaf Extract Improves an Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer's Disease Patients
  Condition or outcome area: chronic inflammation; Alzheimer's disease
  Nutrients · 2022 · Subject: Bai Guo Shu Pi; 白果树皮; Ginkgo Bark; Ginkgo Biloba · open the herb record · DOI 10.3390/nu14102022
• Publication PMID 34805278 Research model: Animal Experiment
  Cardioprotective Properties of Ginkgo Biloba Extract 80 via the Activation of AKT/GSK3β/β-Catenin Signaling Pathway
  Condition or outcome area: myocardial infarction; acute myocardial infarction
  Front Mol Biosci · 2021 · Subject: Bai Guo Shu Pi; 白果树皮; Ginkgo Bark; Ginkgo Biloba · open the herb record · DOI 10.3389/fmolb.2021.771208
• Publication PMID 34520829 Research model: Animal Experiment
  Systemic and topical Ginkgo biloba leaf extract (Egb-761) ameliorated rat paw inflammation in comparison to dexamethasone
  Condition or outcome area: inflammatory disease conditions; carrageenan-induced rat paw edema; rat paw edema
  J Ethnopharmacol · 2021 · Subject: Bai Guo Shu Pi; 白果树皮; Ginkgo Bark; Ginkgo Biloba · open the herb record · DOI 10.1016/j.jep.2021.114619
• Publication PMID 33492645 Research model: Animal Experiment
  Ginkgo biloba Extract (GbE) Restores Serotonin and Leptin Receptor Levels and Plays an Antioxidative Role in the Hippocampus of Ovariectomized Rats
  Condition or outcome area: hippocampal disorders
  Mol Neurobiol · 2021 · Subject: Bai Guo Shu Pi; 白果树皮; Ginkgo Bark; Ginkgo Biloba · open the herb record · DOI 10.1007/s12035-021-02281-5
• Publication PMID 32015684 Research model: Clinical Experiment
  Ginkgo biloba extract attenuates the disruption of pro-and anti-inflammatory T-cell balance in peripheral blood of arsenicosis patients
  Condition or outcome area: Arsenicosis; arsenicosis
  Int J Biol Sci · 2020 · Subject: Bai Guo Shu Pi; 白果树皮; Ginkgo Bark; Ginkgo Biloba · open the herb record · DOI 10.7150/ijbs.39351
• Publication PMID 31963184 Research model: Animal Experiment
  Anti-Obesity Effect of Ginkgo Vinegar, a Fermented Product of Ginkgo Seed Coat, in Mice Fed a High-Fat Diet and 3T3-L1 Preadipocyte Cells
  Nutrients · 2020 · Subject: Bai Guo; 白果; Ginkgo Seed; Ginkgo Semen; Semen Ginkgo · open the herb record · DOI 10.3390/nu12010230
• Publication PMID 26748714 Research model: Cell Experiment
  Endogenous TRIM5α Function Is Regulated by SUMOylation and Nuclear Sequestration for Efficient Innate Sensing in Dendritic Cells
  Cell Rep · 2016 · Subject: Ginkgolic acid; 22910-60-7; Ginkgolic acid C15:1; Ginkgoic acid; Ginkgolic acid I; Gingkolic Acid; 2-hydroxy-6-[(Z)-pentadec-8-enyl]benzoic acid; 6-[(8Z)-Pentadecenyl]-salicylic acid; Romanicardic acid; CHEBI:5354 · open the ingredient record · DOI 10.1016/j.celrep.2015.12.039
• Publication PMID 31970286 Research model: Cell Experiment
  Ginkgolic Acid, a SUMO-1 Inhibitor, Inhibits the Progression of Oral Squamous Cell Carcinoma by Alleviating SUMOylation of SMAD4
  Mol Ther Oncolytics · 2019 · Subject: Ginkgolic acid; 22910-60-7; Ginkgolic acid C15:1; Ginkgoic acid; Ginkgolic acid I; Gingkolic Acid; 2-hydroxy-6-[(Z)-pentadec-8-enyl]benzoic acid; 6-[(8Z)-Pentadecenyl]-salicylic acid; Romanicardic acid; CHEBI:5354 · open the ingredient record · DOI 10.1016/j.omto.2019.12.005
• Publication PMID 30472463 Research model: Animal & Cell Experiment
  Ginkgetin, a biflavone from Ginkgo biloba leaves, prevents adipogenesis through STAT5-mediated PPARγ and C/EBPα regulation
  Condition or outcome area: obesity
  Pharmacol Res · 2019 · Subject: Ginkgetin; 481-46-9; 7,4'-Dimethylamentoflavone; Amentoflavone 7,4'-dimethyl ether; CHEBI:5353; HY5EZW8269; 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxochromen-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)chromen-4-one; DTXSID70197416; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-(5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl)-2-(4-hydroxyphenyl)-; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)- · open the ingredient record · DOI 10.1016/j.phrs.2018.11.027